WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoANTIRETRO-VIRALS - Benefit/Risk balance remains strongly positive for combination antiretroviral therapy
Ver el documentoCYPROTERONE ACETATE & ETHINYL-ESTRADIOL - Update on risk of venous thromboembolism
Ver el documentoDIETHYL-STILBESTROL - Gynaecological and obstetric complications after in utero exposure
Ver el documentoEPHEDRA - Moves to reduce risks of ephedra-containing products
Ver el documentoFLUTICASONE PROPIONATE - Reports of adrenal crisis
Ver el documentoGRAPEFRUIT JUICE - Revised advice from ADRAC
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - Risk of dementia
Ver el documentoOMEPRAZOLE, RABEPRAZOLE - Reports of interstitial nephritis
Ver el documentoROFECOXIB, CELECOXIB - Case reports support causal association with liver toxicity
Ver el documentoROSIGLITA-ZONE, PIOGLITAZONE - Adverse reactions update
Ver el documentoSOMATROPIN - Not to be authorized for AIDS-related wasting syndrome
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

FLUTICASONE PROPIONATE - Reports of adrenal crisis

Australia. Adverse Drug Reactions Advisory Committee (ADRAC) in Australia has received 10 reports of inhaled corticosteroid-associated adrenal crisis. Eight cases involved children aged 3 10 years who had received fluticasone propionate (Flixotide) 250 1500 µg/day; in six cases, the daily dose was > 500µg, the upper limit recommended by The Thoracic Society of Australia and New Zealand and by The National Asthma Council in Australia, before referral to a respiratory physician. The committee notes that higher fluticasone propionate doses may not confer greater efficacy and prescribers are reminded that "inhaled corticosteroids should be given at the lowest effective dose and reviewed regularly".

Reports in WHO-file: Adrenal insufficiency 100

Reference:
Australian Adverse Drug Reactions Bulletin 22: 6, Apr 2003.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019